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lo the Editor: Platelet response to clopidogrel is characterized by
arge interindividual response variability (1). Numerous studies
ave linked low responsiveness to clopidogrel with the occurrence
f thrombotic events, and more recently, data have emerged
inking an enhanced response to clopidogrel with a higher risk for
leeding (2). Both associations have important implications for
atient outcomes, as both thrombotic and bleeding events signif-
cantly affect mortality (3). With the advent of more potent P2Y12
eceptor inhibitors such as prasugrel and ticagrelor, an important
uestion to be addressed is whether the association of ischemic
vents with the level of P2Y12 receptor inhibition is a linear and
hereby continuous association (the more inhibition, the lower the
isk for ischemic events) or whether it is characterized by a certain
hreshold effect. The latter would mean that below a certain
hreshold value of adenosine diphosphate-induced platelet aggre-
ation, ischemic events could not be further reduced, but in
ontrast, bleeding events may substantially increase. The existence
f efficacy and safety thresholds for patients treated with long-term
ntithrombotic therapy has been well established with coumarin
erivatives (4).
Because we have previously been able to establish cutoff values
f adenosine diphosphate-induced platelet aggregation using the
ultiplate analyzer (Dynabyte Informationssysteme GmbH, Mu-
ich, Germany) for the occurrence of both stent thrombosis (ST)
5) and major bleeding events (2), we sought to analyze the
ncidence of bleeding and ST comparatively across different levels
f P2Y12 receptor inhibition to explore threshold effects and a
otential therapeutic window for clopidogrel treatment.
Patients (n  2,533) included in this study underwent
oronary stenting after pre-treatment with clopidogrel 600 mg.
denosine diphosphate-induced platelet aggregation was as-
essed using a Multiplate analyzer on blood samples obtained
irectly before percutaneous coronary intervention. Aggrega-
ion values are quantified in aggregation units (AU) times
inutes ( area under the aggregation curve). For the present
nalysis, the primary efficacy end point was the 30-day inci-
ence of definite or probable ST, and the primary safety end
oint was the incidence of in-hospital Thrombolysis In Myo-
ardial Infarction major bleeding. As previously reported, dif-
erent levels of P2Y12 receptor inhibition were defined by cutoff
alues derived from receiver-operating characteristic curve anal-
ses with a cutoff value of 468 AU  min to define clopidogrel
ow responders (5) and a cutoff value of 188 AU  min to define
nhanced responders (2).
Details of the study population have been reported previously2). A median platelet aggregation value of 225 AU  min Winterquartile range 142 to 374 AU  min) was observed. Using
he cutoff values of 188 and 468 AUmin, patients were allocated
o 3 different groups: 975 patients (38%) were classified as enhanced
esponders (188 AU min), 428 patients (17%) as low responders
468 AU  min), and 1,130 patients (45%) as normal responders
189 to 467 AUmin). The primary efficacy end point was observed
n 22 patients (0.9%; 16 definite ST and 6 probable ST), and the
rimary safety end point (major bleeding) was observed in 34 patients
1.3%). The incidence of ST was highest (2.8%) in low responders,
nd the incidence of bleeding was highest in enhanced responders
2.2%) (Fig. 1A). For ST, no significant differences were observed
etween normal and enhanced responders (p  0.38). Similarly, no
ignificant differences were observed for the incidence of major
leeding between normal and low responders (p 0.72). The overall
ncidence of adverse events (combined ST and major bleeding) across
he 3 groups of patients is shown in Figure 1B. The risk of adverse
vents was significantly lower in normal responders compared with
he remaining patients (n  1,403; odds ratio: 0.40; 95% confidence
nterval: 0.22 to 0.75; p  0.003).
To the best of our knowledge, this is the first comparative
nalysis of the risk for bleeding and ST across different levels of
2Y12 receptor inhibition. Our findings support the notion that
he association of P2Y12 receptor inhibition and ST is character-
zed by a certain threshold effect, as the incidence of ST does not
ontinuously decrease across increasing levels of P2Y12 receptor
nhibition. A similar relationship seems to be valid for bleeding
vents as well, as no significant differences were observed for
leeding risk when comparing normal and low responders. The
resent analysis provides support for the existence of a “sweet spot”
f P2Y12 receptor inhibition, or a so-called therapeutic window, as
atients with aggregation values in the range of 189 to 467 AU 
in showed remarkably low risk for the occurrence of both
leeding and ST.
The proportion of the population classified as being en-
anced responders here was nearly 40%. Considering the
ecognized variability in the metabolism and active metabolite
eneration of clopidogrel, this is a relatively high percent of
atients to be achieving what appears to be greater than
ecessary levels of P2Y12 inhibition. In contrast, 20% of
atients were unable to achieve adequate levels of platelet
nhibition. With a much greater proportion of patients achiev-
ng too high rather than too low levels of platelet inhibition,
hese results, if confirmed, will have important implications for
he application of treatment strategies designed to increase
evels of P2Y inhibition in large, unselected populations.12
hether these findings are translatable to nonthienopyridine
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July 20, 2010:317–202Y12 inhibitors or to the setting of long-term therapy is
nclear and requires further study.
Although limitations of this analysis, including a single-time
oint assessment of platelet function, the lack of a uniformly
ccepted bleeding definition, and its observational design, need to
e recognized, we do think that the present analysis supports the
ypothesis that the association of P2Y12 receptor inhibition and
schemic events is characterized by a threshold phenomenon and
hat a therapeutic window of P2Y12 receptor inhibition does exist,
ith patients within this range exhibiting low risk for both
leeding and ST.
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aliwango et al. (1) recently provided a beautiful coronary com-
uted tomographic angiographic illustration of a rare anomaly,oronary artery variant (arising from the right coronary cusp and
oursing the entire atrioventricular groove before terminating in
he anterior interventricular sulcus) is certainly uncommon, it is
ot “new” to the literature. This coronary artery anomaly was
reviously identified on the post-mortem examination of the lateFigure 1 Adverse Events and Levels of P2Y12 Receptor Inhibition
(A) Thirty-day incidence of definite or probable stent thrombosis (ST) (black
line) and incidence of in-hospital major bleeding events (red line). Patients are
stratified into groups of enhanced responders (area under the aggregation
curve [AUC] 188), normal responders (AUC 189 to 467), and low responders
(AUC 468). (B) Incidence of adverse events (combined for ST and major
bleeding) across responder groups. p values reported were calculated across
all 3 groups using chi-square tests.asketball star Pete Maravich (2). Histology revealed patchy
